Researchers at the University of Bergen, Norway, have discovered a potential cause behind pediatric cancer. Their findings could lead to the earlier detection of the disease in children. The study, published in Frontiers in Immunology on October 14, demonstrates that children with pediatric cancer are more likely to produce autoantibodies targeting proteins vital for normal DNA repair. Remarkably, these antibodies were present years before the children were diagnosed with cancer.
Childhood cancer, although rare, commonly manifests as blood cancers such as leukemia and lymphoma, along with tumors in the brain, spinal cord, and bones. Adults, on the other hand, more frequently experience lung, breast, colon, prostate, and skin cancer. This distinction highlights the different cellular origins between childhood and adult cancers.
Understanding Autoantibodies
Autoantibodies are a malfunctioning type of antibody. While antibodies fight off germs and viruses, autoantibodies mistakenly target healthy tissues, leading to autoimmune diseases such as type 1 diabetes, lupus, and multiple sclerosis. The exact cause of their production is still unclear, but factors may include infections, environmental toxins, and genetics.
Findings from the Research
The study analyzed tumor and blood samples from 175 individuals with sarcoma or acute lymphoblastic leukemia between 2014 and 2017. Samples were sourced from various biobanks and compared with healthy controls, including blood donors and children from the Bergen Growth Study.
Children with pediatric cancer aged two to 19 demonstrated a notably higher presence of IgG class antibodies. These antibodies primarily target the RAD52, NUMA1, ALKBH7, APBB1, UNG, and MGMT genes, integral to DNA repair.
Professor Ola Myklebost explained that patient autoantibodies could enter cells, bind and restrict proteins outside the nucleus, hindering DNA repair. This mechanism increases mutation rates and cancer risk, evidenced by the detection of autoantibodies being eight times more prevalent in school children who later developed cancer.
Dr. Yvonne Saenger emphasized the significance of differing immune responses between cancer patients and healthy individuals. Further research is needed to assess the impact of these antibodies on cellular processes.
Implications of the Study
Professor Myklebost noted the hypothesis extends beyond childhood cancer, possibly affecting young adults and even adults. The aim is to prove causality and identify the specific autoantibody patterns critical to cancer development. Screening children for these antibodies could assess cancer risk and potentially lead to interventions to inhibit their activity.
The research suggests penetrating autoantibodies may play a role in various human diseases, according to Anastassia Serguienko, senior researcher at the University of Bergen. Future studies should focus on understanding the mechanisms and biology of these autoantibodies.
